TY - JOUR
T1 - Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution
AU - Kovac, Michal B.
AU - Navas, Carolina
AU - Horswell, Stuart
AU - Salm, Max
AU - Bardella, Chiara
AU - Rowan, Andrew
AU - Stares, Mark
AU - Castro Giner, Francesc
AU - Fisher, Rosalie
AU - de Bruin, Elza C.
AU - Kovacova, Monika
AU - Gorman, Maggie
AU - Makino, Seiko
AU - Williams, Jennet
AU - Jaeger, Emma
AU - Jones, Angela
AU - Howarth, Kimberley
AU - Larkin, James
AU - Pickering, Lisa
AU - Gore, Martin
AU - Nicol, David L.
AU - Hazell, Steven
AU - Stamp, Gordon
AU - O'Brien, Tim
AU - Challacombe, Ben
AU - Matthews, Nik
AU - Phillimore, Benjamin
AU - Begum, Sharmin
AU - Rabinowitz, Adam
AU - Varela, Ignacio
AU - Chandra, Ashish
AU - Horsfield, Catherine
AU - Polson, Alexander
AU - Tran, Maxine
AU - Bhatt, Rupesh
AU - Terracciano, Luigi M.
AU - Eppenberger-Castori, Serenella
AU - Protheroe, Andrew
AU - Maher, Eamonn
AU - El Bahrawy, Mona A.
AU - Fleming, Stewart
AU - Ratcliffe, Peter
AU - Heinimann, Karl
AU - Swanton, Charles
AU - Tomlinson, Ian
PY - 2015/3/19
Y1 - 2015/3/19
N2 - Papillary renal cell carcinoma (pRCC) is an important subtype of kidney cancer with a problematic pathological classification and highly variable clinical behaviour. Here we sequence the genomes or exomes of 31 pRCCs, and in four tumours, multi-region sequencing is undertaken. We identify BAP1, SETD2, ARID2 and Nrf2 pathway genes (KEAP1, NHE2L2 and CUL3) as probable drivers, together with at least eight other possible drivers. However, only ~10% of tumours harbour detectable pathogenic changes in any one driver gene, and where present, the mutations are often predicted to be present within cancer sub-clones. We specifically detect parallel evolution of multiple SETD2 mutations within different sub-regions of the same tumour. By contrast, large copy number gains of chromosomes 7, 12, 16 and 17 are usually early, monoclonal changes in pRCC evolution. The predominance of large copy number variants as the major drivers for pRCC highlights an unusual mode of tumorigenesis that may challenge precision medicine approaches.
AB - Papillary renal cell carcinoma (pRCC) is an important subtype of kidney cancer with a problematic pathological classification and highly variable clinical behaviour. Here we sequence the genomes or exomes of 31 pRCCs, and in four tumours, multi-region sequencing is undertaken. We identify BAP1, SETD2, ARID2 and Nrf2 pathway genes (KEAP1, NHE2L2 and CUL3) as probable drivers, together with at least eight other possible drivers. However, only ~10% of tumours harbour detectable pathogenic changes in any one driver gene, and where present, the mutations are often predicted to be present within cancer sub-clones. We specifically detect parallel evolution of multiple SETD2 mutations within different sub-regions of the same tumour. By contrast, large copy number gains of chromosomes 7, 12, 16 and 17 are usually early, monoclonal changes in pRCC evolution. The predominance of large copy number variants as the major drivers for pRCC highlights an unusual mode of tumorigenesis that may challenge precision medicine approaches.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Antibodies, Monoclonal/chemistry
KW - Carcinoma, Renal Cell/genetics
KW - Chromosome Mapping
KW - Chromosomes/ultrastructure
KW - DNA Copy Number Variations
KW - Exome
KW - Exons
KW - Female
KW - Gene Expression Regulation, Neoplastic
KW - Histone-Lysine N-Methyltransferase/genetics
KW - Humans
KW - Kidney Neoplasms/genetics
KW - Loss of Heterozygosity
KW - Male
KW - Middle Aged
KW - Mutation
KW - Phylogeny
KW - Polymorphism, Single Nucleotide
KW - Sequence Analysis, DNA
U2 - 10.1038/ncomms7336
DO - 10.1038/ncomms7336
M3 - Article
C2 - 25790038
SN - 2041-1723
VL - 6
JO - Nature Communications
JF - Nature Communications
M1 - 6336
ER -